Concepedia

Daniel Quirk

DQ

Statistics

Publications

10

Citations

510

H-Index

10

Active since

1992

Affiliations

Pfizer (United States)(Current)

Icahn School of Medicine at Mount Sinai

Nutrition-Génétique et Exposition aux Risques Environnementaux

Impact Technology Development (United States)

Université de Lorraine

Daniel Quirk is an author at Pfizer (United States) specializing in inflammatory bowel disease, pharmacotherapy, and ulcerative colitis pharmacotherapy.

Publications per year

1992–2020

10

Publications

10

Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis

Stephen B. Hanauer, Remo Panaccione, Silvio Danese et al. · Clinical Gastroenterology and Hepatology · 2018 · 185 citations · Full text

, , +17

Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis

William J. Sandborn, Laurent Peyrin‐Biroulet, Daniel Quirk et al. · Clinical Gastroenterology and Hepatology · 2020 · 83 citations · Full text

, , +16

Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe

Alessandro Armuzzi, Marco daCosta DiBonaventura, M. Tarallo et al. · PLoS ONE · 2020 · 59 citations · Full text

, , +15

Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis

Jean‐Frédéric Colombel, Mark T. Osterman, Andrew Thorpe et al. · Clinical Gastroenterology and Hepatology · 2020 · 39 citations

, , +13

Secretory immune system of the male reproductive tract: effects of dihydrotestosterone and estradiol on IgA and secretory component levels

Judy E. Stern, Susan Gardner, Daniel Quirk et al. · Journal of Reproductive Immunology · 1992 · 36 citations

, , +16

1–5 of 10